Results 51 to 60 of about 24,961 (203)

Perspectives and practices of ototoxicity monitoring

South African Journal of Communication Disorders, 2020
Background: Treatment of cancer with cisplatin can result in hearing loss. Given the increasing burden of cancer in Africa, appropriate and timely identification, intervention and management of hearing loss in affected patients is of paramount importance.
Jessica Paken, Cyril D. Govender, Mershen Pillay, Vikash Sewram   +3 more
doaj   +1 more source

Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium.

The Lancet Oncology, 2019
Childhood, adolescent, and young adult (CAYA) cancer survivors treated with platinum-based drugs, head or brain radiotherapy, or both have an increased risk of ototoxicity (hearing loss, tinnitus, or both).
E. Clemens, M. M. van den Heuvel-Eibrink, R. Mulder, L. Kremer, M. Hudson, R. Skinner, L. Constine, J. Bass, C. Kuehni, T. Langer, E. V. van Dalen, E. Bárdi, N. Bonne, P. Brock, B. Brooks, B. Carleton, Eric Caron, Kay W Chang, K. Johnston, K. Knight, P. Nathan, E. Orgel, P. Prasad, J. Rottenberg, K. Scheinemann, A. D. de Vries, Thomas Walwyn, A. Weiss, A. am Zehnhoff-Dinnesen, R. Cohn, W. Landier   +30 more
semanticscholar   +1 more source

Navigating the Genetic Risk of Chemotherapy‐Induced Hearing Loss in the Stria Vascularis

Clinical Pharmacology &Therapeutics, EarlyView.
Cisplatin is a chemotherapy drug that causes permanent hearing loss by damaging a critical tissue lining the inner ear, called the stria vascularis (SV). Currently, the molecular mechanisms of SV damage are largely unknown and the incidence of ototoxicity in patients cannot be reliably predicted.
Tara Lazetic, Deanne Nixie R. Miao, Britt I. Drögemöller, Alain Dabdoub, Julia M. Abitbol   +4 more
wiley   +1 more source

Healthcare professionals’ knowledge and practices in managing ototoxicity in children with cancer

South African Journal of Communication Disorders
Background: Platinum-based chemotherapy poses a risk of ototoxic hearing loss, the effects of which can be devastating in paediatrics with cancer. Childhood hearing loss significantly impacts speech and language acquisition, and educational, psychosocial
Kajal Ramnarian, Jessica Paken
doaj   +1 more source

Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline.

The Lancet Child & Adolescent Health, 2019
Despite ototoxicity being a prevalent consequence of cisplatin chemotherapy, little guidance exists on interventions to prevent this permanent and progressive adverse event. To develop a clinical practice guideline for the prevention of cisplatin-induced
D. Freyer, D. Freyer, P. Brock, Kay W Chang, L. Dupuis, S. Epelman, K. Knight, D. Mills, R. Phillips, Emma Potter, D. Risby, P. Simpkin, Michael J. Sullivan, Michael J. Sullivan, Sandra Cabral, P. Robinson, L. Sung   +16 more
semanticscholar   +1 more source

Adjunctive Hyperbaric Oxygen Therapy or Intratympanic Steroids in Sudden Sensorineural Hearing Loss?

The Laryngoscope, EarlyView.
Sudden sensorineural hearing loss is traditionally treated with steroids, either orally and/or via intratympanic injections, and hyperbaric oxygen treatment (HBOT) has resurged in popularity as an adjunctive therapy. The study has not found any additional treatment benefit with adjunctive concurrent HBOT; however, HBOT might be of value to patients ...
Jennifer L. Spiegel, Michael J. De Biasio, Gianluca Sampieri, Omer J. Ungar, Munir D. Bajin, Vincent Y. W. Lin, Joseph M. Chen, Chris Idestrup, Jordan Tarshis, Trung N. Le   +9 more
wiley   +1 more source

Mechanisms of Cisplatin-Induced Ototoxicity and Prevention

Seminars in Hearing, 2019
Cisplatin is a highly effective antineoplastic agent used to treat solid tumors. Unfortunately, the administration of this drug leads to significant side effects, including ototoxicity, nephrotoxicity, and neurotoxicity.
L. Rybak, D. Mukherjea, V. Ramkumar
semanticscholar   +1 more source

Mesna in Otologic Surgery: Efficacy and Safety—A Scoping Review

The Laryngoscope, EarlyView.
PRISMA flow diagram indicating the process of systematic inclusion and exclusion of articles. ABSTRACT Objective Mesna (Sodium 2‐mercaptoethanesulfonate) is widely used as a mucolytic agent and uroprotective agent. Recently, its disulfide bond‐breaking property has been applied in otologic surgery to facilitate safer dissection of cholesteatoma and ...
Kevork H. Atamian, Inabat Yermesheva, Ostap Orishchak, Hady Tall, Sam J. Daniel   +4 more
wiley   +1 more source

A real-world pharmacovigilance analysis of potential ototoxicity associated with sacubitril/valsartan based on FDA Adverse Event Reporting System (FAERS)

Scientific Reports
Sacubitril/valsartan, a first-in-class angiotensin receptor neprilysin inhibitor, is widely used to treat heart failure. Despite its efficacy, sacubitril/valsartan inevitably causes adverse events such as hypotension, renal dysfunction, hyperkalemia, and
Ning Wang, Haijun Wang, Ying Chen, Yanfeng Wang   +3 more
doaj   +1 more source

Rate of Hearing Loss in Platinum‐Naïve Patients Receiving Immune Checkpoint Inhibitors

Otolaryngology–Head and Neck Surgery, EarlyView.
Abstract Objective Hearing loss from immune checkpoint inhibitors (ICIs) has been documented in case reports and case series. We present the largest retrospective study investigating the rate of ICI‐related ototoxicity in a monitored cohort of platinum‐naïve patients. Study Design Retrospective cohort study. Setting Tertiary‐care center.
Kaitlyn A. Brooks, Christopher G. Gidley, Olivia Grimley, Catherine Wang, Shirin Jivani, Dianna Roberts, Aung Naing, Jack Phan, Katherine Hutcheson, Xin Wang, Paul W. Gidley, Marc‐Elie Nader   +11 more
wiley   +1 more source